Sedana Medical says FDA accepts NDA for isoflurane ICU sedation system for review

• Sedana Medical NDA for isoflurane via its ACD Delivery System accepted for FDA review in U.S. mechanically ventilated adult ICU sedation.
• FDA to set a PDUFA target action date within the next weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sedana Medical AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.